Director's dealing

RNS Number : 5692Y

Yourgene Health PLC

09 May 2019

 

Yourgene Health plc

("Yourgene," the "Company")

Director's dealing

Manchester, UK - 9 May 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has been notified today that Dr Stephen Little, a director of the Company, has purchased 448,452 ordinary shares of 0.10p each in the Company today at a price of 11.2 pence per ordinary share.

Following the purchase, Dr Stephen Little holds 6,026,736 ordinary shares in the Company representing 1.0% of the Company's issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:
Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing [e-mail]	Tel: [phone]
Cairn Financial Advisers LLP (NOMAD) Liam Murray / James Caithie	Tel: [phone]
Stifel Nicolaus Europe Limited (Broker) Nicholas Moore / Matthew Balwat / Ben Maddison	Tel: [phone]
Vigo Communications Ben Simons / Fiona Henson / Antonia Pollock [e-mail]	Tel: [phone]

About Yourgene Health 

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.

Yourgene Health's first commercialised products are NIPT for Down's Syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.

Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Dr Stephen Little
2	Reason for notification
a.	Position/Status	Vice Chairman
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Yourgene Health plc
b.	LEI	213800UUIT8BZE7QEH33
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 0.10p each ISIN: GB00BN31ZD89
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			11.2p	448,452
e.	Date of the transaction	9 May 2019
f.	Place of the transaction	London Stock Exchange

 

END

 

 

DSHEASSNEESNEFF